{"filing":{"accession_number":"0001213900-26-110669","cik":"0001544227","ticker":"TPST","company_name":"Tempest Therapeutics, Inc.","form":"8-K","filing_date":"2026-10-19","report_date":"2026-10-13","primary_document":"ea0309028-8k_tempest.htm","primary_document_url":"https://www.sec.gov/Archives/edgar/data/1544227/000121390026110669/ea0309028-8k_tempest.htm"},"events":[{"id":36057,"run_id":33242,"accession_number":"0001213900-26-110669","anchor_item_number":"5.02","event_type":"exec_appointment","event_domain":"governance","is_material":true,"confidence":0.95,"summary":"Tempest Therapeutics appointed John Frederick as a Class III director, effective October 13, 2026. The appointment was announced via press release on October 14, 2026, highlighting his extensive executive leadership experience in financial strategy, capital markets, and corporate governance. Frederick received an initial option award of 25,000 shares as part of his director compensation.","company_name":"Tempest Therapeutics, Inc.","ticker":"TPST","filing_date":"2026-10-19","form":"8-K","submitted_at":null,"items":[{"id":40330,"accession_number":"0001213900-26-110669","item_number":"5.02","item_title":"Departure of Directors or Certain Officers; Election","event_type":"exec_appointment","event_domain":"governance","is_material":true,"confidence":0.95,"reasoning":"The filing discloses the appointment of John Frederick as a Class III director of Tempest Therapeutics, effective October 13, 2026. The principal disclosed action is a person taking a role on the board. While the disclosure also mentions compensatory arrangements (an initial option award of 25,000 shares), the core event is the director appointment itself. This is material to investors as it reflects board composition changes and brings relevant financial and capital markets expertise to a clinical-stage biotech company.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-10-19T20:06:51.974257+00:00","company_name":"","ticker":null,"filing_date":""},{"id":40331,"accession_number":"0001213900-26-110669","item_number":"7.01","item_title":"Regulation FD Disclosure.","event_type":"exec_appointment","event_domain":"governance","is_material":true,"confidence":0.95,"reasoning":"The filing discloses the appointment of John W. Frederick to Tempest's board of directors, announced via press release on October 14, 2026. The press release emphasizes his extensive executive leadership experience in financial strategy, capital markets, and corporate governance, and the CEO explicitly states his financial acumen and strategic leadership will be \"particularly valuable\" to the company. This is a clear board appointment of a named executive with material expertise relevant to the company's capital strategy and governance.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-10-19T20:06:51.974257+00:00","company_name":"","ticker":null,"filing_date":""}]}],"classifications":[{"id":40330,"accession_number":"0001213900-26-110669","item_number":"5.02","item_title":"Departure of Directors or Certain Officers; Election","event_type":"exec_appointment","event_domain":"governance","is_material":true,"confidence":0.95,"reasoning":"The filing discloses the appointment of John Frederick as a Class III director of Tempest Therapeutics, effective October 13, 2026. The principal disclosed action is a person taking a role on the board. While the disclosure also mentions compensatory arrangements (an initial option award of 25,000 shares), the core event is the director appointment itself. This is material to investors as it reflects board composition changes and brings relevant financial and capital markets expertise to a clinical-stage biotech company.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-10-19T20:06:51.974257+00:00","company_name":"Tempest Therapeutics, Inc.","ticker":"TPST","filing_date":"2026-10-19"},{"id":40331,"accession_number":"0001213900-26-110669","item_number":"7.01","item_title":"Regulation FD Disclosure.","event_type":"exec_appointment","event_domain":"governance","is_material":true,"confidence":0.95,"reasoning":"The filing discloses the appointment of John W. Frederick to Tempest's board of directors, announced via press release on October 14, 2026. The press release emphasizes his extensive executive leadership experience in financial strategy, capital markets, and corporate governance, and the CEO explicitly states his financial acumen and strategic leadership will be \"particularly valuable\" to the company. This is a clear board appointment of a named executive with material expertise relevant to the company's capital strategy and governance.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-10-19T20:06:51.974257+00:00","company_name":"Tempest Therapeutics, Inc.","ticker":"TPST","filing_date":"2026-10-19"}]}